Meeting
2021 ASCO Annual Meeting
KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC).
Authors
Chung-Han Lee
Memorial Sloan Kettering Cancer Center, New York, NY
Chung-Han Lee , Chenxiang Li , Rodolfo F. Perini , Daniela Hoehn , Laurence Albiges
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT04704219
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4595)
DOI
10.1200/JCO.2021.39.15_suppl.TPS4595
Abstract #
TPS4595
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
An open-label phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706).
First Author: Akihito Kawazoe
Poster
2019 ASCO Annual Meeting
Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to anti–PD-1/PD-L1 agents: Phase 2 LEAP-004 study.
First Author: ANA Maria Arance Fernandez
Poster
2024 ASCO Genitourinary Cancers Symposium
A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in patients with renal cell carcinoma with brain metastasis previously treated with immune checkpoint blockade.
First Author: Elshad Hasanov
Poster
2023 ASCO Annual Meeting
A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
First Author: Maliheh Mohamadpour